AstraZeneca Pharma shares rose on receiving nod from the CDSCO, to import for sale and distribution of Benralizumab 30 mg/ml ...

Bangalore: AstraZeneca Pharma India Limited has received regulatory approval from the Central Drugs Standard Control ...

Through this approval, Benralizumab is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).

A new study published in the journal of CHEST showed that benralizumab reduces exacerbations, especially in older individuals ...

Anti–interleukin five (IL-5) biologics such as mepolizumab and benralizumab have shown significant efficacy in reducing ...

The study evaluated 807 adults who initiated an anti–IL–5 therapy (79% mepolizumab, 21% benralizumab) between 2017 and 2020.

Clinical remission was achieved and sustained in nearly one third of patients with severe eosinophilic asthma (SEA) receiving benralizumab for up to 2 years, with better outcomes in biologic-naive ...

These medications include benralizumab and dupilumab injections. Emphysema is a type of chronic obstructive pulmonary disease (COPD) that occurs when the air sacs in the lungs lose elasticity or ...

A real-life, retrospective, observational, comparative European cohort study was conducted among patients with EGPA who received either benralizumab or mepolizumab at the dose used for the ...

People taking benralizumab were significantly less likely to need further treatment for their asthma or COPD symptoms, a major clinical trial has shown ...

But what if there was a better option? Advt Our latest study, published in The Lancet Respiratory Medicine, has revealed that a drug called benralizumab - administered as an injection - may be the ...

(RTTNews) - Researchers at King's College London have found a new treatment for asthma attacks, which could be a "game-changer" for the patients. Lead investigator Prof Mona Bafadhel, of King's ...